Log In
Print
BCIQ
Print
Print this Print this
 

MGCD265

  Manage Alerts
Collapse Summary General Information
Company Mirati Therapeutics Inc.
DescriptionOral small molecule, multitargeted kinase inhibitor that targets the c-Met, VEGF receptors 1, 2, 3, Tie-2 and RON receptor tyrosine kinases
Molecular Target c-Met receptor tyrosine kinase ; Vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) (VEGFR-2)
Mechanism of ActionVascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) kinase inhibitor; Vascular endothelial growth factor (VEGF) receptor 1 (Flt-1) kinase inhibitor; c-Met receptor tyrosine kinase inhibitor; AXL receptor tyrosine kinase (AXL) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today